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ABSTRACT 
 
 
 
 
The purpose of this research is to develop a unique nanoparticulate system that is 
capable of delivering antibiotics in a locally applied and extended-release manner for 
patients receiving cranial replacement implants and bone grafting. This study involves 
three major components: first, encapsulate both hydrophobic antibiotics 
(chloramphenicol and rifampicine) and hydrophilic antibiotics (vancomycine and 
acyclovir) into nanoparticles. Second, incorporate antibiotic nanoparticles in a polymeric 
coating material (nitrocellulose plus 7.0% (w/v) polyvinylpyrrolidone) with a volatile 
carrier solvent (ethyl acetate or ethanol).  Third, directly apply the resulting product from 
component 1 and 2 to polymethyl methacrylate (PMMA) cranial implants and 
hydroxylapatite (HA) bone grafting materials directly before surgery.  
When the volatile carrier solvent evaporates, the coating polymer with embedded 
antibiotic nanoparticles will form a thin film that is capably attached to the surface of the 
implant material. Local application of encapsulated antibiotics directly to the surgical 
sites can provide a non-oral, non-intravenous, controlled time-release treatment, which 
would allow continuous administration of antibiotic therapy over the prescribed time 
span of the individual antibiotics used. This study will provide a novel chemotherapeutic 
regime for the prevention and treatment of bacterial, fungal, and viral infections often 
occurred in cranial/bone transplant patients with a more efficient effective dose. The 
main advantage of this study is reduction of problems with antibiotics administered 
through oral route such as multi drug resistance, systemic toxicity due to high doses 
and first pass metabolism. This study has several advantages such as size and efficacy 
of nanoparticles, sustained release due to nanoparticulate antibiotics and non-toxic.  
 
 
INTRODUCTION 
 
 
The proposed study involves the incorporation of encapsulated antibiotic 
nanoparticles in a polymer (such as poly methylacrylate-isobutene-
monoisopropylmaleate) with an alcohol carrier solvent.  When the carrier solvent 
evaporates, the polymer with embedded nanoparticles will form a thin film that is 
capably attached to any surface it will have been applied to. This product can be directly 
applied to polymethyl methacrylate (PMMA) cranial implants and hydroxylapatite bone 
grafting materials. PMMA is a synthetic, transparent plastic, biocompatible polymer 
which has been used in many medical applications since 1933.4,5 Cured PMMA has a 
Young’s modulus between that of human cancellous bone and cortical bone.5 The high 
surface area and low density characteristics make PMMA an excellent material for 
seeding and coating antibiotic encapsulated nanoparticles. This specific targeting drug 
delivery system can help reduce dangerous side effects. It also eliminates the time that 
would otherwise be needed for the drugs to be processed by the liver.  Therefore, a 
lesser amount of drug will have the same beneficiary effects compared to the drugs 
being administered intravenously or orally.  
                        
  
Vancomycine has been one of the primary antibiotics used in blast injured 
patents, as it is effective against both aerobic and anaerobic bacterial infections.6 
usually clindamycin is administrated orally, absorbed from the gastrointestinal tract, 
extensively metabolized in the liver, and then distributed throughout the body. A small 
therapeutic concentration (between 5 to 10 percent) can be achieved in the brain after 
1.5 to 5 hours of administration of the drug.7 Since it has to be systematic circulated, a 
much higher initial dose is needed for the effective dosage to reach the brain.  However, 
higher initial dosages cause more severe side effects including headache, bloody 
diarrhea, fever, nausea, severe blisters of the skin, jaundice, etc.; 8   these can probably 
be reduced by administrating the effective dosage directly to the infected area.  
 
It has been shown that drug delivery systems using nanoparticle-encapsulated 
antibiotics can improve antimicrobial efficacy against drug-resistant strains.9,10 
Nanoparticles such as liposomes and micelles can protect drugs by isolating them from 
systemic degrading enzymes and promoting their diffusion across the bacterial 
envelope.9-11 Liposomes are colloidal lipid-bilayer vesicles ranging from a few 
nanometers to several micrometers.12 Hydrophilic drugs such as vancomycine  can be 
safely trapped in the center of aqueous compartments . Micelles, on the other hand, 
usually are used to encapsulate hydrophobic material (Figure 2). However, in this study, 
by using a micro emulsion method, inverse micelles can be produced and trap 
hydrophilic clindamycin in its core. Inverse micelles are generally smaller, tighter and 
more stable than liposomes. Therefore, by manipulating the concentrations and sizes 
between liposomes and inverse micelles, control release of encapsulated antibiotics 
over time can be achieved.  
               
 
 
Normal micelles (Figure 2) have a hydrophobic core and a hydrophilic surface allowing 
the encapsulation of hydrophobic molecules in an aqueous solution. Inverse (or 
reverse) micelles, with a hydrophilic core, are created by using the microemulsion 
method. This type of micelle is specifically used to encapsulate hydrophilic molecules. 
Liposomes (Figure 2) have a double membrane and can encapsulate both hydrophilic 
molecules (in their core) and hydrophobic molecules (in the lipid bilayer) in an aqueous 
solution. Inverse micelles are generally smaller, tighter and more stable than regular 
micelles and liposomes. Therefore, by manipulating the concentrations and sizes 
between them, controlled release of encapsulated antibiotics over time can be 
achieved. The combination of inverse micelles and liposomes can be used for the 
encapsulation of any hydrophilic (water soluble) antibiotic such as vancomycin and 
cephalosporin for bacterial infections, aciclovir for viral infections, and amphotericin B 
for fungal infections. A Combination of regular micelles and lipsosomes can be used for 
the encapsulation of hydrophobic antibiotics such as novobiocin, rifampicin, 
spectnomycin, and trimethoprim. .  
 
Local application of encapsulated antibiotic directly to the brain after placement of 
cranial implants can provide non-oral and controlled time release of the drug which 
would allow continuous administration of antibiotics over 2 weeks with minimum side 
effects. We believe this study will provide a novel chemotherapeutic regime for the 
prevention and treatment of bacterial infections in cranial/bone transplant patients.  
 
EXPERIMENTAL METHODS 
1. PMMA Implant 
The human skull is divided into two parts, the cranium and the face skeleton. In this 
study, we are focusing on the cranium. The cranium, which lodges and protects the                                                                                                                                                                  
brain, consists of 8 bones: the occipital, 2 parietals, the frontal, 2 temporal, the 
sphenoid, and the ethmoid. For cranial implantation, parietal bones are the most 
commonly replaced by artificial materials. We have developed four formulations for the 
cranial implant:  
Formulation 1-A: 18 g of polymethyl methacrylate (PMMA) + 12 mL methyl 
methacrylate (MMA)  
Formulation 1-B: 18 g PMMA + 12 mL MMA + 8 mL ethyl methacrylate (EMA) 
Formulation 1-C: 16 g PMMA + 12 mL MMA + 8 mL isobutyl methacrylate (acryloid B-
67, an adhesive) + 2 mL methyl ethyl ketone peroxide (MEKP, a catalyst) 
Formulation 1-D: 20 g PMMA + 15 mL MMA + 14 mL isobutyl methacrylate + 0.75 mL 
MEKP 
Formulation 1-E: 8 g PMMA + 6 mL MMA + 3 mL isobutyl methacrylate (acryloid B-67, 
an adhesive) + 0.3 mL methyl ethyl ketone peroxide (MEKP, a catalyst) 
Formulation 1-F: 12 g PMMA + 5 mL MMA + 3mL ethyl methacrylate (EMA) 
Thoroughly mix the above formulation separately on a hotplate in a chemical hood with 
constant stirring. Cast the mixture in a molding plate (Al or Sn molding plate) with the 
desired thickness. The usual adult skull is about 5.0 to 8.0 mm in thickness (with female 
average of 7.1 mm and male of 6.5 mm); the pediatric skull is about 2.0 mm in 
thickness. Place the casting plate in the oven ( 2 hours for the adult implant and I hour 
for the pediatric implant) at 80 oC in order for the PMMA to cure. The tensile strength of 
PMMA implants is tested using a machine called an Instron. Tensile strength is 
generally measured in N/cm2, the normal human skull has a tensile strength of 7,053 
N/cm2 and the tensile strength of our formulation 1-A  to 1-D has either equal or greater 
the average tensile strength value of the human skull. 
 
2. Reverse Micelles (W/O Emulsion) 
Formula 2-A: 
I. Mix 2.2 grams of AOT in 5 mL of vitamin E (or Vitamin F). Gently heated and 
stirred continuously.  
II. Once the AOT is dissolved, add 2 mL of water + drug (water phase) drop by drop 
with constant stirring. 
III. Sonicate for 15 minutes.   
Liposomes and Formula 2-A were designed to encapsulate and deliver hydrophilic 
drugs. The hydrophobic drugs are known to be more difficult to be transported into the 
targeted cells. Therefore, we have created a unique formulation to encapsulate and 
deliver hydrophobic antibiotics.  
 
 
3. O/W/O Nanoparticles 
Formula 3-A: 
I.  The Hydrophobic anti-bacterial drug chloramphenicol and 500 M pa lmitic  
or steric acid are dissolved in 10 mL of ethyl acetate (the first oil phase). 
II.  The first oil phase is then titrated into a 20 mL water phase containing 500 M 
PEG200 with constant stirring. Micelles are formed in this o/w emulsion. 
III. Kept stirring until all the ethyl acetate from the first oil phase is evaporated (by 
bringing the volume down to 20 mL - the original volume of the water phase). 
Nanoparticles are formed with chloramphenicol entrapped inside the micelles. 
IV.  12 or 18 % w/v of polycaprolactone (PCL) and 500 M pa lmitic    
acid are dissolved in ethyl acetate by stirring at 50°C (the final oil phase). 
V. Remove the heat; add nanoparticles from step III drop by drop into the final oil 
phase with constant stirring. Continue stirring until the solution reaches room 
temperature. PCL fibers then form a thin layer surrounding the double layered 
nanoparticles. 
 
4. Coating Material 
Formula 4-A: 
I.  Dissolve 0.2 g of polycaprolactone in 2.0 mL of nitrocellulose and 2.0 mL of 
acetone with constant stirring under very low heat. 
II.    Add acetone drop by drop in the beaker until the polymer is totally dissolved. 
 
Usually liquid bandage contains 7% alcohol in its formulation. Our coating formula 
follows the common liquid bandage formulation with slight modifications. We use FDA 
approved material in order to avoid the long governmental approval and evaluation 
process, therefore the final product can be available to consumers as soon as possible. 
We use nitrocellulose as our primary ingredient in our coating material. When 
nitrocellulose is dissolved in ether or alcohol, collodion is formed. When collodion dries, 
a flexible cellulose film is produced. Besides nitrocellulose, 2-octyl cyanoacrylate and n-
butyl cyanoacrylate can also be used as the primary ingredient in the coating 
formulation. The main advantage of these materials is they do not break down in the 
body to form any toxic byproducts.  
 
5. Stabilizer and Thickening Agent 
2.5% w/v of human collagen will be added to all the above formulations as a stabilizer. 
Carbomer, a synthetic high molecular weight polymer of acrylic acid will be used as a 
thickening agent to increase the viscosity of all the formulations.  
 
RESULTS 
 
1. PMMA Implant 
SEM images of the surfaces of PMMA implant materials show different depth of grooves 
which are capable of embedding the liposomes and nanoparticles.  
Formulation 1-A:  
 
 
 
 
 
 
 
 
 
  
  
 Formulation 1-B:  
 
 
 
 
 
 
 
 
 
 
Formulation 1-C 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
2. Liposomes and Nanoparticles 
 
Electron microscopy (EM) is commonly used nowadays to capture high-resolution 
imaging of liposomes and nanoparticles. However, EM requires that samples be placed 
in a vacuum and is not quite suitable for examining wet samples such as ours. The only 
means of imaging a wet sample with EM is to freeze or dry it, thus changing its nature in 
the process. In our study, we use the QuantomiX capsules methodology developed by 
WETSEM®.  This technique eliminates many of the artifacts that result when preparing 
wet samples for EM. This technology enables imaging of our samples that contain oily 
and volatile solvent. 
 
TEM OF NANOPARTICLES 
 
                       
 
NANOPARTICLES AT DIFFERENT MAGNIFICATION 
 
 
Fluorescence study is the  secondary technique which was used to provide an evidence 
for encapsulation of drug in to nanoparticles and examine the nanoparticle. The graph 
provieds a good evidence for the encapsulation of the drug in to the nanoparticles. 
Graph shows a decreased intensity of fluorescence of drug in water when compared to 
that of the drug in the revrse micelle which indicates that drug is encapsulated in to the 
revrse micelle. Liposomes have more decreased fluorescence intensity when compared 
to that of the reverse micelle this is because of the multi lamellar structure of the 
liposomes.  
 
EVIDENCE FOR ENCAPSULATION 
 
 
 
 
3. Controlled Release Study 
 
Human cerebrospinal fluid (CSF) was used to examine the controlled release kinetics. A 
luminescence marker was  encapsulated inside our reverse micelle and nanoparticles 
instead of the antibiotic in order to monitor the controlled release. Riboflavin was used  
to simulate the hydrophobic drug and florencene dye was used  to simulate the 
hydrophilic drug.  The nanoparticulate drug was coated on to the PMMA implants using 
the coating material. The final product (a PMMA implant coated with encapsulated 
luminescence marker) was be submerged inside the human cerebrospinal fluid and the 
fluorescence was  measured at 0, 1, 2, 3, 4, 6,  7, 8, 9, 10, 20, 30, 40, 52, 64, 76, 100 
and 124 hours. The intensity of fluorescence indicates the amount of drug that is 
released from the coating polymer into the cerebrospinal fluid. For the hydrophilic drug, 
formulation 2-A will hold onto the drug longer for more sustained and  delayed release. 
Formulation 3-A will be for the prolonged release due to slow biodegrading period of the 
PCL polymer that surrounds the nanoparticles. 
 
S.NO TIME (IN HRS) FlUORESCENCE 
INTENSITY 
DRUG 
RELEASE (µg) 
% RELEASE 
1 0hrs 0 0 µg 0% 
2 1hrs 0 0 µg 0% 
3 2hrs 1752 4.25 µg 3.79% 
4 3hrs 1838 4.46 µg 3.98% 
5 4hrs 1927 4.67 µg 4.16% 
6 6hrs 2043 4.95 µg 4.41% 
7 7hrs 2126 5.15 µg 4.59% 
8 8hrs 2392 5.80 µg 5.17% 
9 9hrs 2482 6.02 µg 5.37% 
10 10hrs 2605 6.32 µg 5.64% 
11 20hrs 2838 6.88 µg 6.14% 
12 30hrs 3164 7.67 µg 6.84% 
13 40hrs 3642 8.83 µg 7.88% 
14 52hrs 4002 9.71 µg 8.66% 
15 64hrs 4531 10.99 µg 9.81% 
16 76hrs 4642 11.26 µg 10.05% 
17 100hrs 5286 12.82 µg 11.44% 
 
The above table shows the results for controlled release study. From the fluorescence 
intensity obtained the amount of drug released was calculated and from the amount of 
drug released % drug released was calculated. Once the percentage of drug released 
was calculated a graph was plotted taking % drug released on Y-axis and time on X-
axis.  
 
 
CONTROLLED RELEASE FROM REVERSE MICELLE 
 
  
4. Cytotoxicity Test 
 
Toxicity of our formulations will be examined by using the standard BCA test. Human 
brain glial cells (SVG p12 cell line) will be purchased from American Type Cell 
Collection (ATCC). The subculture procedures will follow the protocol published by 
ATCC. Each formulation will be tested to ensure its’ safety.   
 
DISCUSSION 
 
 
 
The following study “ Encapsulated Antibiotic Nanoparticles for Cranial 
Transaplantation” has the ability to prevent bacterial infections in cranial transplantation.    
preparation of antibiotics in a nanoparticulate form can be used to prevent infections  in  
cranial transplantation with lesser side effects when compared to that of the antibiotics 
prepared for oral administration. The antibiotic drug prepared in nanoparticulate form 
can be directly applied to the  location of surgery which reduces the first pass 
metabolism. PMMA implants used in cranial implantation  were prepared and were 
observed to have a tensile strength of 7053N/cm2 which is similar to that of the tensile 
strenght of the human brain skull. SEM images of PMMA implant shows depth groves 
which indicates the capability of embedding the nanoparticles. Fluorescence studies 
show that the  drug is completely encapsulated in to the prepared reverse micelle 
nanoparticles. TEM images shows the formation ans size of the nanoparticles. 
Controlled relase study results indicated that the prepared nanoparticles provided 
sustained release of the drug for about 15 days. Cytotoxicity test are to be performed 
inorder to test the toxicity of the formulation. Furthur research can be done by preparing 
different types of  formulations of nanoparticles and by using different types of drugs. 
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